List view / Grid view
10 April 2014 | By Abbott
Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold...
11 June 2013 | By Abbott
Trial to study the innovative "dissolving" heart device...
4 June 2013 | By Abbott
Publication of positive outcomes...
21 May 2013 | By Abbott
Abbott announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System...
20 March 2013 | By Abbott
"We appreciate the FDA's dedication of time and resources..."
10 March 2013 | By Abbott
Data from the EVEREST II study...
8 January 2013 | By Abbott
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States...
20 August 2012 | By Abbott
XIENCE Xpedition™ Everolimus Eluting Coronary Stent System receives CE Mark...
7 August 2012 | By Abbott
The U.S. FDA has approved the Omnilink Elite® Vascular Balloon-Expandable Stent System...
15 May 2012 | By Abbott
New indication supported by data from more than 10,000 patients...
7 March 2012 | By Abbott
The U.S. FDA approved the Absolute Pro® Vascular Self-Expanding Stent System...
8 December 2011 | By Abbott
Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial...
4 October 2011 | By Abbott
Abbott's EXCEL is the largest trial to date designed to evaluate optimal treatment strategy in patients with unprotected left main disease...
8 September 2011 | By Abbott
Abbott announced the initiation of ABSORB BTK...
10 August 2011 | By Abbott
The U.S. FDA approved the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis...
